Pharmacoeconomic Study on the Application of Magnetic Resonance Imaging with Gadoxetic Acid in Addition to Contrast-Enhanced Computed Tomography in Diagnosis of Hepatocellular Carcinoma-Reference-Cited by-同舟云学术

Pharmacoeconomic Study on the Application of Magnetic Resonance Imaging with Gadoxetic Acid in Addition to Contrast-Enhanced Computed Tomography in Diagnosis of Hepatocellular Carcinoma

Published:2021-11-17 Issue:5 Volume:102 Page:284-295
ISSN:2619-0478
Container-title:Journal of radiology and nuclear medicine
language:
Short-container-title:Vestn. rentgenol. radiol.

Author:

Kаrmаzаnovsky G. G.¹^ORCID,Volobueva A. A.²^ORCID

Affiliation:

1. Vishnevsky National Medical Research Center of Surgery, Ministry of Health; Pirogov Russian National Research Medical University, Ministry of Health

2. Bayer JSC

Abstract

Objective: to evaluate pharmacoeconomic advantages of the application of magnetic resonance imaging (MRI) with hepatobiliary-specific contrast agent – gadoxetic acid in addition to contrast-enhanced computed tomography (CT) in the diagnosis of hepatocellular carcinoma (HCC).Material and methods. We performed the modeling and obtained the results of the pharmacoeconomic study: effectiveness analysis, cost analysis, and cost-effectiveness analysis. The cost analysis included only direct medical costs (the cost of contrast-enhanced CT, gadolinium-based contrast agent (GBCA) for MRI, and therapy per a patient with verified HCC diagnosis after diagnostic procedures). The financing was performed from the Compulsary Health Insurance Fund. The calculations were made per 1 patient.Results. The effectiveness analysis showed that the diagnostic scheme CT + MRI with gadoxetic acid was the most effective complex for the diagnosis of HCC because its application provided 50% of patients with 5-year overall survival (4.8 years), which was significantly higher than in patients who were diagnosed HCC with CT + MRI with extracellular GBCA (2.3 years) or CT (3.7 years). The cost-effectiveness analysis showed that the diagnostic scheme with gadoxetic acid was dominant because each disability-adjusted life year required fewer costs (14 862 rubles) in comparison with CT + MRI with extracellular GBCA (25 293 rubles) or CT (46 540 rubles). According to the results of the incremental cost-effectiveness ratio analysis, the application of the diagnostic complex with gadoxetic acid was characterized by the lowest rate of additional costs per 1 disability-adjusted life year.Conclusion. The pharmacoeconomic study showed that the application of MRI with a hepatospecific contrasting agent – gadoxetic acid in addition to contrast-enhanced CT was an effective and economically beneficial method of early HCC diagnosis.

Publisher

Luchevaya Diagnostika

Subject

General Medicine

Reference23 articles.

1. Coleman WB. Mechanisms of human hepatocarcinogenesis. Curr Mol Med. 2003; 3(6): 573–88. https://doi.org/10.2174/1566524033479546.

2. Lalazar G, Sanford MS. Fibrolamellar carcinoma: recent advances and unresolved questions on the molecular mechanisms. Semin Liver Dis. 2018; 38(1): 51–9. https://doi.org/10.1055/s-0037-1621710.

3. European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018; 69(1): 182–236. https://doi.org/10.1016/j.jhep.2018.03.019.

4. Omata M, Cheng AL, Kokudo N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017; 11(4): 317–70. https://doi.org/10.1007/s12072-017-9799-9.

5. Breder VV, Balakhnin PV, Virshke ER, et al. Practical recommendations for drug treatment of patients with hepatocellular carcinoma. Malignant Tumors. 2021; 10(3s2–1): 450–69. https://doi.org/10.18027/2224-5057-2020-10-3s2-25 (in Russ.).